ArticleCase reports in pulmonology2025
Diagnostic Approach in a Rare Lung Tumor: Inflammatory Myofibroblastic Tumor.
Article in Case reports in pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Approach in a Rare Lung Tumor: Inflammatory Myofibroblastic Tumor.Case reports in pulmonology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis and management of inflammatory myofibroblastic tumors (IMTs) are challenging due to limited data and complications with existing techniques. We report a case of IMT in which a patient was found to have a rare near-total obstructive endobronchial tumor in the left mainstem bronchus after two unsuccessful bronchoscopy attempts-the second attempt requiring intubation due to significant bleeding, which is a common finding in IMTs. We suggest using cryorecanalization for tumor debulking to minimize the risk of bleeding during bronchoscopies and to follow up with argon plasma coagulation (APC) for safe management. The patient tolerated this procedure well with no complications and had improved symptoms, emphasizing the importance of innovative patient-tailored care to treat rare and complex lung tumors such as IMTs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.